Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy
Pulmonary Arteriovenous Malformations
About this trial
This is an interventional treatment trial for Pulmonary Arteriovenous Malformations focused on measuring Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia (HHT), Embolization, reperfusion rates
Eligibility Criteria
Inclusion Criteria:
Patients are eligible for inclusion in the study if all the following criteria are met:
- Documented presence of new (untreated) pulmonary AVMs requiring embolization
- Definite clinical diagnosis of HHT or genetic diagnosis of HHT
- Age ≥18 years
- Able to provide informed consent
Exclusion Criteria:
Patients will be excluded from the study if, in the opinion or knowledge of the Principal Investigator any of the following criterion is present:
- Participants with multiple AVMs within close proximity where identification of the aneurysm seen on CT cannot be precisely isolated for randomization purposes.
Contra-indications to embolotherapy
- Severe chronic renal failure, without availability of dialysis
- Severe pulmonary hypertension (PA systolic estimated at >60mmHg)
Sites / Locations
- St. Michael's Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Interlock fibered IDC Occlusion System
Nestor Coil
Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
Pulmonary angiography and embolotherapy technique using Nestor coils